Healthcare focus Athyrium Capital Management specializes in the global healthcare sector, presenting opportunities to align with them on healthcare-focused investment strategies, royalty acquisitions, and structured credit deals related to biopharma and medtech.

Recent asset moves Active deal activity in 2026 includes buying and financing arrangements such as a $50M royalty/asset purchase from Esperion and a $30M convertible note investment in Hansa Biopharma, signaling continued appetite for healthcare royalties and equity-like instruments.

Growth through partnerships Engagement with top-tier law firms and strategic controllers (e.g., Mannheimer Swartling) and collaboration with portfolio companies suggests openness to structured financing, M&A advisory, and cross-border legal support for complex healthcare transactions.

Financial size and scope Revenue range reported at $25M-$50M with a lean company size (11-50 employees) indicates a nimble firm likely receptive to scalable financial products, credit facilities, and selective equity or royalty financing that fit mid-sized asset managers.

Tech and outreach Utilizes a modern stack (CRM, marketing automation, consent and analytics tools) highlighting readiness for targeted outreach, personalized communications, and lifecycle campaigns to source health-tech and biopharma investment opportunities.